Haplotype-Based Analysis of Genes Associated With Risk of Adverse Skin Reactions After Radiotherapy in Breast Cancer Patients
Creators
- Suga, Tomo1
- Ishikawa, Atsuko1
- Kohda, Masakazu1
- Otsuka, Yoshimi1
- Yamada, Shigeru2
- Yamamoto, Naohito3
- Shibamoto, Yuta4
- Ogawa, Yoshihiro5
- Nomura, Kuninori6
- Sho, Keizen7
- Omura, Motoko8
- Sekiguchi, Kenji9
- Kikuchi, Yuzo10
- Michikawa, Yuichi1
- Noda, Shuhei1
- Sagara, Masashi1
- Ohashi, Jun11
- Yoshinaga, Shinji12
- Mizoe, Junetsu2
- Tsujii, Hirohiko2
- and others
- 1. RadGenomics Project, National Institute of Radiological Sciences, Chiba (Japan)
- 2. Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba (Japan)
- 3. Chiba Cancer Center, Chiba (Japan)
- 4. Nagoya City University Hospital, Aichi (Japan)
- 5. Tohoku University Hospital, Miyagi (Japan)
- 6. Toyama University Hospital, Toyama (Japan)
- 7. Shiga University of Medical Science Hospital, Shiga (Japan)
- 8. Yokohama City University Hospital, Kanagawa (Japan)
- 9. St. Luke's International Hospital, Tokyo (Japan)
- 10. Kanazawa University Hospital, Ishikawa (Japan)
- 11. Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo (Japan)
- 12. Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba (Japan)
Description
Purpose: To identify haplotypes of single nucleotide polymorphism markers associated with the risk of early adverse skin reactions (EASRs) after radiotherapy in breast cancer patients. Methods and Materials: DNA was sampled from 399 Japanese breast cancer patients who qualified for breast-conserving radiotherapy. Using the National Cancer Institute-Common Toxicity Criteria scoring system, version 2, the patients were grouped according to EASRs, defined as those occurring within 3 months of starting radiotherapy (Grade 1 or less, n = 290; Grade 2 or greater, n = 109). A total of 999 single nucleotide polymorphisms from 137 candidate genes for radiation susceptibility were genotyped, and the haplotype associations between groups were assessed. Results: The global haplotype association analysis (p < 0.05 and false discovery rate < 0.05) indicated that estimated haplotypes in six loci were associated with EASR risk. A comparison of the risk haplotype with the most frequent haplotype in each locus showed haplotype GGTT in CD44 (odds ratio [OR] = 2.17; 95% confidence interval [CI], 1.07-4.43) resulted in a significantly greater EASR risk. Five haplotypes, CG in MAD2L2 (OR = 0.55; 95% CI, 0.35-0.87), GTTG in PTTG1 (OR = 0.48; 95% CI, 0.24-0.96), TCC (OR = 0.48; 95% CI, 0.26-0.89) and CCG (OR = 0.50; 95% CI, 0.27-0.92) in RAD9A, and GCT in LIG3 (OR = 0.46; 95% CI, 0.22-0.93) were associated with a reduced EASR risk. No significant risk haplotype was observed in REV3L. Conclusion: Individual radiosensitivity can be partly determined by these haplotypes in multiple loci. Our findings may lead to a better understanding of the mechanisms underlying the genetic variation in radiation sensitivity and resistance among breast cancer patients
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2007.06.021Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2007.06.021;
- PII
- S0360-3016(07)01140-6;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 69
- Journal Issue
- 3
- Journal Page Range
- p. 685-693
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 39059569
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; DNA; GENES; HEALTH HAZARDS; MAMMARY GLANDS; NUCLEOTIDES; PATIENTS; RADIOSENSITIVITY; RADIOTHERAPY; SKIN; TOXICITY
- Descriptors DEC
- BODY; DISEASES; GLANDS; HAZARDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; SENSITIVITY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.